The Vertical Group is a venture capital firm that is focused on the fields of medical technology and biotechnology. The principals of the vertical group have been founders, early stage investors, major shareholders, and executives of many of the medical technology industry's most successful companies. The Vertical Group is the successor to the venture capital division of F. Eberstadt & Co., and has been an independent firm since 1988.
The Vertical Group has made 51 investments as of 2018. Their most recent investment was on Mar 5, 2018, when Biorez raised $1.5M. The Vertical Group has had 14 exits. The Vertical Group's most notable exits include Silk Road Medical, OncoMed Pharmaceuticals, and TetraLogic Pharmaceuticals. The Vertical Group has raised a total of $10M in a single venture fund, Vertical Fund II. This fund was announced on Jan 23, 2006 and raised a total of $10M.
ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.
Silk Road Medical is a Sunnyvale, California-based healthcare company.
A life sciences company focused on protein research using nanoproteomics
Outset Medical is a San Jose, California-based medical device company.
Kaira Nithin Goud